The Exacerbation of Lutembatcher Syndrome in The Setting of COVID-19 infection: A Rare Case Report
Downloads
Lutembatcher syndrome is a rare cardiac condition characterized by a combination of the atrial septal defect (ASD; congenital or iatrogenic) and mitral stenosis (MS; congenital or acquired). Patients with Lutembatcher syndrome and adults with congenital heart disease (ACHD) in general may be at high risk when accompanied by coronavirus disease 2019 (COVID-19). Since there is no published study on the impact of COVID-19 on ACHD, little is known about management strategies in this subset of patients. Herein, we report a young adult female presented with abdominal discomfort, swollen legs, fever, cough, and dyspnea. The patient had developed palpitation and exercise intolerance five years ago but paid it no attention. Echocardiography revealed large secundum type ASD with severe MS (Wilkins score of eight) and a nasopharyngeal swab confirmed SARS-COV-2 infection. The patient was diagnosed with Lutembacher syndrome and COVID-19. Intensive treatment was given to relieve symptoms due to heart failure and to treat COVID-19 pneumonia. Patients with Lutembatcher syndrome are at a higher risk of being infected with COVID-19 and manifest into severe infections. Therefore, determining the risk of infection and the severity of COVID-19 in ACHD patients are required during the pandemic.
Keywords: Adults with congenital heart disease, Coronavirus disease 2019, Lutembacher
Lutembacher R. De la sténose mitrale avec communication interauriculaire. Arch Mal Coeur. 1916;9:237–60.
Vaideeswar P, Marathe S. Lutembacher's syndrome: Is the mitral pathology always rheumatic? Indian Heart J. 2017;69(1):20–3.
World Health Organization. Situation report [Internet]. Vol. 2020, World Health Organization. 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76(April 2020):71–6.
Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. Am J Respir Crit Care Med. 2020 Apr;
Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020;10:1–10.
Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020 Apr;
Radke RM, Frenzel T, Baumgartner H, Diller G-P. Adult congenital heart disease and the COVID-19 pandemic. Heart. 2020;
Aminde LN, Dzudie AT, Takah NF, Ambassa JC, Mapoh SY, Tantchou JC. Occurrence of Lutembacher syndrome in a rural regional hospital: case report from Buea, Cameroon. Cardiovasc Diagn Ther. 2014;4(3):263.
Mahajan K, Oliver TI. Lutembacher syndrome. In: StatPearls [Internet]. StatPearls Publishing; 2019.
Tezcan M, Isilak Z, Atalay M, Uz O. Echocardiographic assessment of Lutembacher syndrome. Kardiol Pol (Polish Hear Journal). 2014;72(7):660.
Aminde LN, Dzudie A, Takah NF, Ngu KB, Sliwa K, Kengne AP. Current diagnostic and treatment strategies for Lutembacher syndrome: the pivotal role of echocardiography. Cardiovasc Diagn Ther. 2015;5(2):122.
Reményi B, Wilson N, Steer A, Ferreira B, Kado J, Kumar K, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease”an evidence-based guideline. Nat Rev Cardiol. 2012;9(5):297–309.
Phan QT, Nguyen HL, Le TD, Lee W, Won H, Shin S, et al. Combined percutaneous procedure in patient with Lutembacher syndrome: a case report and real-world experience review. Cardiol Res. 2018;9(6):385.
Goel S, Nath R, Sharma A, Pandit N, Wardhan H. Successful percutaneous management of Lutembacher syndrome. Indian Heart J. 2014;66(3):355–7.
Baumgartner H, De Backer J, Babu-Narayan S V, Budts W, Chessa M, Diller G-P, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. :ehaa554.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;
Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130(9):749–56.
Committee on Infectious Diseases. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):e620–38.
Bare I, Crawford J, Pon K, Farida N, Dehghani P. Frequency and consequences of influenza vaccination in adults with congenital heart disease. Am J Cardiol. 2018;121(4):491–4.
Ferrero P, Piazza I, Ciuffreda M. COVID-19 in adult patients with congenital heart disease A matter of anatomy or comorbidities? Cardiol Young. 2020;1–10.
Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(12):e81–192.
British Congenital Cardiac Association. BCCA COVID-19 guidance for Vulnerable groups with congenital heart disease (18 March 2020) [Internet]. 2020. Available from: https://www.bcca-uk.org/pages/news_box.asp?NewsID=19495710
Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2020 Apr;127:104362.
Belen E, Özal E, Püsüroğlu H. Relationship between the presence of left atrial thrombus in patients with mitral stenosis and platelet-to-lymphocyte ratio. Anatol J Cardiol. 2016;16(9):673.
Cardiology ES of. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. ESC. 2020;
Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020 Apr;
Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int J Cardiol. 2020 Mar;
Heiberg J, Nyboe C, Hjortdal VE. Impaired ventilatory efficiency after closure of atrial or ventricular septal defect. Scand Cardiovasc J. 2017;51(4):221–7.
Copyright (c) 2022 Adriyawan Widya Nugraha
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- Cardiovascular and Cardiometabolic Journal (CCJ) is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
-
Authors who publish with Cardiovascular and Cardiometabolic Journal (CCJ) agree to the following terms:
-
The journal allows the author to hold the copyright of the article without restrictions.
-
The journal allows the author(s) to retain publishing rights without restrictions.
-
The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution ShareAlike 4.0 International License (CC BY-SA).
